US FDA wants more data on Pfizer's Fablyn
This article was originally published in Scrip
Executive Summary
The US FDAhas issued Pfizerwith a complete response letter asking for more data on its selective oestrogen receptor modulator (SERM), Fablyn (lasofoxifene). The product is currently under review for the treatment of osteoporosis in postmenopausal women at increased risk of bone fracture.